{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:53:54Z","timestamp":1789012434227,"version":"build-2803163510"},"reference-count":133,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cardfail.2024.07.013","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T09:04:29Z","timestamp":1728378269000},"page":"1343-1354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anticoagulation Medications, Monitoring, and Outcomes in Patients with Cardiogenic Shock Requiring Temporary Mechanical Circulatory Support"],"prefix":"10.1016","volume":"30","author":[{"given":"Chirag","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel R.","family":"Sodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halley C.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliese","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Poppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar N","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dawn","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-8238","authenticated-orcid":false,"given":"Saraschandra","family":"Vallabhajosyula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2024.07.013_bib0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ccd.30786","article-title":"Escalation strategies, management, and outcomes of acute myocardial infarction-cardiogenic shock patients receiving percutaneous left ventricular support","volume":"102","author":"Patlolla","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010193","article-title":"Temporary mechanical circulatory support for refractory cardiogenic shock before left ventricular assist device surgery","volume":"7","author":"Vallabhajosyula","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2018.10.029","article-title":"Trends, predictors, and outcomes of temporary mechanical circulatory support for postcardiac surgery cardiogenic shock","volume":"123","author":"Vallabhajosyula","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0004","first-page":"503","article-title":"Venoarterial extracorporeal membrane oxygenation in cardiogenic shock","volume":"6","author":"Keebler","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0005","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1038\/s41598-020-64702-0","article-title":"Cardiogenic shock elicits acute inflammation, delayed eosinophilia, and depletion of immune cells in most severe cases","volume":"10","author":"Cuinet","year":"2020","journal-title":"Sci Rep"},{"issue":"Supplement_2","key":"10.1016\/j.cardfail.2024.07.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.1538","article-title":"Acquired von Willebrand syndrome in left Impella-supported cardiogenic shock patients","volume":"41","author":"Vandenbriele","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0007","doi-asserted-by":"crossref","first-page":"e1343","DOI":"10.4244\/EIJ-D-19-00428","article-title":"Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in ITaly: the IMP-IT registry","volume":"15","author":"Chieffo","year":"2020","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-62703-339-8_12","article-title":"Activated clotting time (ACT)","volume":"992","author":"Horton","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0009","first-page":"21","article-title":"Changes in transfusion therapy guided by thromboelastography in cardiac surgery","volume":"4","author":"Manikappa","year":"2001","journal-title":"Ann Card Anaesthes"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/bja\/86.4.575","article-title":"Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass","volume":"86","author":"Royston","year":"2001","journal-title":"Br J Anaesthes"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0011","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1540-8191.2009.00840.x","article-title":"Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study","volume":"24","author":"Ak","year":"2009","journal-title":"J Card Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13613-017-0352-8","article-title":"Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study","volume":"8","author":"Panigada","year":"2018","journal-title":"Ann Intens Care"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the APTT for monitoring unfractionated heparin?","volume":"157","author":"Arachchillage","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1527-3466.2005.tb00177.x","article-title":"Bivalirudin: pharmacology and clinical applications","volume":"23","author":"Shammas","year":"2005","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0016","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","article-title":"Heparin-induced thrombocytopenia","volume":"67","author":"Salter","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0017","first-page":"1459","article-title":"Intraoperative management of adult patients on extracorporeal membrane oxygenation: an expert consensus statement from the Society of Cardiovascular Anesthesiologists: Part I, technical aspects of extracorporeal membrane oxygenation","volume":"133","author":"Mazzeffi","year":"2021","journal-title":"Anesth Analg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0018","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MBC.0b013e328201c9a9","article-title":"Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography","volume":"18","author":"Young","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0019","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/asheducation-2018.1.516","article-title":"An introduction to point-of-care testing in extracorporeal circulation and LVADs","volume":"2018","author":"Bercovitz","year":"2018","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/labmed\/lmz014","article-title":"Intraoperative monitoring of heparin: comparison of activated coagulation time and whole blood heparin measurements by different point-of-care devices with heparin concentration by laboratory-performed plasma anti-Xa assay","volume":"50","author":"Thompson","year":"2019","journal-title":"Lab Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0022","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4054806","article-title":"Clinical scenarios for discordant anti-Xa","volume":"2016","author":"Vera-Aguilera","year":"2016","journal-title":"Adv Hematol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1097\/PCC.0000000000000028","article-title":"Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*","volume":"15","author":"Liveris","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0025","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/0267659114524264","article-title":"Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients","volume":"29","author":"Atallah","year":"2014","journal-title":"Perfusion"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0026","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1309\/AJCPGVD62LKKVDLH","article-title":"Evaluation of heparin assay for coagulation management in newborns undergoing ECMO","volume":"134","author":"Khaja","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0027","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.5858\/arpa.2013-0572-OA","article-title":"The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay","volume":"138","author":"Kostousov","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0028","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00063-009-1093-8","article-title":"[Heparin resistance and antithrombin deficiency]","volume":"104","author":"Maurin","year":"2009","journal-title":"Med Klin (Munich)"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0029","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","volume":"21","author":"Helms","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0030","article-title":"Current status and limitation of direct oral anticoagulants testing","volume":"7","author":"Mruthunjaya","year":"2022","journal-title":"Int J Biochem Physiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2257.2005.00681.x","article-title":"Thrombelastography\/thromboelastometry","volume":"27","author":"Luddington","year":"2005","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0032","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1213\/00000539-199902000-00016","article-title":"Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery","volume":"88","author":"Shore-Lesserson","year":"1999","journal-title":"Anesth Analg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1051\/ject\/202052013","article-title":"Platelet mapping by thromboelastography and whole blood aggregometry in adult patients supported by mechanical circulatory support device on aspirin therapy","volume":"52","author":"Volod","year":"2020","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0034","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1053\/j.jvca.2020.07.009","article-title":"Association of adenosine diphosphate-induced platelet maximum amplitude with postoperative bleeding and blood transfusions in patients undergoing coronary artery bypass grafting","volume":"35","author":"Tian","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MAT.0000000000000445","article-title":"Role of thromboelastography platelet mapping and international normalized ratio in defining \"normocoagulability\" during anticoagulation for mechanical circulatory support devices: a pilot retrospective study","volume":"63","author":"Volod","year":"2017","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0036","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0037","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1160\/TH06-07-0362","article-title":"High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes","volume":"97","author":"Cuisset","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0038","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0039","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1309\/AJCPQ9BYJ0OEENGA","article-title":"Platelet mapping assay interference due to platelet activation in heparinized samples","volume":"142","author":"Nelles","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0041","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0042","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.ccm.0000907772.89043.b0","article-title":"511: Use of thromboelastography with platelet mapping for management of antiplatelet-associated bleeding","volume":"51","author":"Longueira","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0043","first-page":"A10175","article-title":"The impact of anticoagulation during intra-aortic balloon counterpulsation pump placement on in-hospital outcomes in 18,875 patients undergoing cardiac revascularization","volume":"122","author":"Chin","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0044","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-0040-1716390","article-title":"Comparison of safety between different kinds of heparins in patients receiving intra-aortic balloon counterpulsation","volume":"69","author":"Guan","year":"2021","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ccd.1810110406","article-title":"Heparin elimination following continuous infusion during intra-aortic balloon counterpulsation","volume":"11","author":"Jacob","year":"1985","journal-title":"Cathet Cardiovasc Diagn"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0046","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/01.ccm.0000998788.86482.cf","article-title":"Complications of heparin with intra-aortic balloon counterpulsation","volume":"52","author":"Nuti","year":"2024","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0047","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0048","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1592\/phco.19.9.760.31547","article-title":"Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time","volume":"19","author":"Rosborough","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0049","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1345\/aph.1Q161","article-title":"Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion","volume":"45","author":"Guervil","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0050","doi-asserted-by":"crossref","DOI":"10.2146\/sp150016","article-title":"Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring","volume":"72","author":"Frug\u00e9","year":"2015","journal-title":"Am J Health-Sys Pharm"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0051","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.semtcvs.2018.10.011","article-title":"Heparin-induced thrombocytopenia and cardiac surgery","volume":"31","author":"Solanki","year":"2019","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0052","first-page":"14","article-title":"Bivalirudin infusion therapy during complete higher risk indicated percutaneous coronary intervention (CHIP) in heparin-induced thrombocytopenia and end-stage renal failure: a case report","volume":"16","author":"Thomas","year":"2023","journal-title":"RCSI"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.jccase.2012.08.001","article-title":"Management of intra-aortic balloon counterpulsation by argatroban anticoagulation in a patient with a history of heparin-induced thrombocytopenia","volume":"6","author":"Tabata","year":"2012","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0054","article-title":"Dabigatran as alternative anticoagulant for intra-aortic balloon pump in a patient with suspected heparin-induced thrombocytopenia","volume":"21","author":"Lee","year":"2013","journal-title":"J Hong Kong Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0056","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0057","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0058","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.amjcard.2007.06.026","article-title":"Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial","volume":"100","author":"Feit","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0059","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0003-4975(98)01139-4","article-title":"Decreased incidence of arterial thrombosis using heparin-bonded intraaortic balloons","volume":"67","author":"Lazar","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12959-021-00295-6","article-title":"Comparison of anticoagulated versus non-anticoagulated patients with intra-aortic balloon pumps","volume":"19","author":"Kelly","year":"2021","journal-title":"Thrombosis J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0061","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1631\/jzus.2003.0607","article-title":"Anticoagulation therapy in intra-aortic balloon counterpulsation: does IABP really need anti-coagulation?","volume":"4","author":"Jiang","year":"2003","journal-title":"J Zhejiang Univ Sci"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0062","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1540-8191.2012.01484.x","article-title":"Heparin-free management of intra-aortic balloon pump after cardiac surgery","volume":"27","author":"Kogan","year":"2012","journal-title":"J Card Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0063","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jtcvs.2012.02.009","article-title":"Benefits of ambulatory axillary intra-aortic balloon pump for circulatory support as bridge to heart transplant","volume":"143","author":"Umakanthan","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0064","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00380-022-02122-y","article-title":"Clinical outcomes of grafted vs. percutaneous axillary intra-aortic balloon pump support as a bridge to transplantation: a propensity score-matched analysis","volume":"37","author":"Nishida","year":"2022","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jchf.2020.01.011","article-title":"Percutaneous left axillary artery placement of intra-aortic balloon pump in advanced heart failure patients","volume":"8","author":"Bhimaraj","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0066","first-page":"305","article-title":"Axillary artery hemostasis post\u2013intra-aortic balloon pump failure","volume":"2","author":"Al-Ani","year":"2020","journal-title":"JACC: Case Rep"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0067","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jjcc.2021.11.010","article-title":"Ten-year, single center experience of ambulatory axillary intra-aortic balloon pump support for heart failure","volume":"79","author":"Nishida","year":"2022","journal-title":"J Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1097\/MAT.0000000000001753","article-title":"Percutaneous right axillary intra-aortic balloon pump in patients with advanced heart failure","volume":"68","author":"Alvarez Villela","year":"2022","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0069","article-title":"SCAI position statement on best practices for percutaneous axillary arterial access and training","volume":"1","author":"Seto","year":"2022","journal-title":"J Soc Cardiovasc Angiogr Intervent"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40119-019-00152-8","article-title":"Complications of temporary percutaneous mechanical circulatory support for cardiogenic shock: an appraisal of contemporary literature","volume":"8","author":"Subramaniam","year":"2019","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0071","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.ccm.0000727240.91210.c4","article-title":"338: Anti-Xa versus aPTT monitoring in patients requiring an Impella device","volume":"49","author":"Girgis","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0072","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/10600280211039582","article-title":"Heparin monitoring with an anti-Xa protocol compared to activated clotting time in patients on temporary mechanical circulatory support","volume":"56","author":"Feih","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0073","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2022.02.052","article-title":"Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock","volume":"79","author":"Vandenbriele","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0074","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ajcp\/99.5.546","article-title":"A review of the clinical indications for the plasma heparin assay","volume":"99","author":"Marci","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0075","doi-asserted-by":"crossref","first-page":"489s","DOI":"10.1378\/chest.114.5_Supplement.489S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0076","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0077","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MAT.0000000000000244","article-title":"Developing an anti-Xa-based anticoagulation protocol for patients with percutaneous ventricular assist devices","volume":"61","author":"Sieg","year":"2015","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0078","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.1843","article-title":"Optimal antithrombotic regimen in patients with cardiogenic shock on ImpellaTM mechanical support: less might be more","volume":"41","author":"Vandenbriele","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0079","unstructured":"Abiomed Inc. Impella ventricular support systems for use during cardiogenic shock and high-risk PCI. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf14\/P140003S018D.pdf. Accessed January 15, 2024."},{"key":"10.1016\/j.cardfail.2024.07.013_bib0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/phar.2356","article-title":"Use of tissue plasminogen activator alteplase for suspected Impella thrombosis","volume":"40","author":"Succar","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0081","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/08971900221089078","article-title":"Use of sodium bicarbonate purge solution in Impella devices for heparin-induced thrombocytopenia","volume":"36","author":"Al-Ayoubi","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0082","series-title":"Paper presented at: ASAIO 66th Annual Conference, June 10\u201312","article-title":"Bicarbonate as an alternative to heparin in Impella purge fluid: understanding the biochemical basis","author":"Gilman","year":"2021"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0083","first-page":"116","article-title":"Bicarbonate purge solution to support Impella devices for patients with clinically suspected or confirmed heparin-induced thrombocytopenia","volume":"67","author":"Moretz","year":"2021","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0084","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0897190020930530","article-title":"Use of systemic bivalirudin and an anticoagulant-free purge solution in a percutaneous left ventricular assist device in a patient with heparin-induced thrombocytopenia","volume":"34","author":"Kazmi","year":"2021","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0085","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.healun.2015.08.018","article-title":"Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device","volume":"34","author":"Anderson","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0086","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.hrtlng.2018.03.009","article-title":"Percutaneous biventricular Impella support in therapy-refractory cardiogenic shock","volume":"47","author":"Chiu","year":"2018","journal-title":"Heart Lung"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0087","article-title":"Hemodynamic support using percutaneous transfemoral Impella 5.0 and Impella RP for refractory cardiogenic shock","volume":"2019","author":"Dalal","year":"2019","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0088","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006670","article-title":"Acute biventricular mechanical circulatory support for cardiogenic shock","volume":"6","author":"Kuchibhotla","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0089","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ehf2.12274","article-title":"Full percutaneous biventricular support with two Impella pumps: the Bi-Pella approach","volume":"5","author":"Pappalardo","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ehf2.12412","article-title":"Minimally invasive biventricular mechanical circulatory support with Impella pumps as a bridge to heart transplantation: a first-in-the-world case report","volume":"6","author":"Varian","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0091","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/aor.14428","article-title":"Outcomes of systemic bivalirudin and sodium bicarbonate purge solution for Impella 5.5","volume":"47","author":"Bashline","year":"2023","journal-title":"Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0092","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0897190017727191","article-title":"Anticoagulation of percutaneous ventricular assist device using argatroban-based purge solution: a case series","volume":"31","author":"Blum","year":"2018","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0093","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/CIRCULATIONAHA.110.008698","article-title":"Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion","volume":"124","author":"Donadee","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0094","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/aor.13319","article-title":"Increased plasma-free hemoglobin levels identify hemolysis in patients with cardiogenic shock and a trans valvular micro-axial flow pump","volume":"43","author":"Esposito","year":"2019","journal-title":"Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10047-020-01172-1","article-title":"Impact of the angle between aortic and mitral annulus on the occurrence of hemolysis during Impella support","volume":"23","author":"Nakamura","year":"2020","journal-title":"J Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0096","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/155698451000500608","article-title":"Thromboembolic events in patients on extracorporeal membrane oxygenation without anticoagulation","volume":"5","author":"Lamarche","year":"2010","journal-title":"Innovations (Phila)"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0097","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MAT.0000000000000442","article-title":"Is stopping heparin safe in patients on extracorporeal membrane oxygenation treatment?","volume":"63","author":"Chung","year":"2017","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0098","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.athoracsur.2019.08.040","article-title":"Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events","volume":"109","author":"Wood","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0099","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/aor.12335","article-title":"Do we need heparin coating for extracorporeal membrane oxygenation? New concepts and controversial positions about coating surfaces of extracorporeal circuits","volume":"39","author":"Silvetti","year":"2015","journal-title":"Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/039139880202500910","article-title":"Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: the intraoperative ECMO concept","volume":"25","author":"Ranucci","year":"2002","journal-title":"Int J Artif Org"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1515\/bmt-2017-0107","article-title":"The peripheral cannulas in extracorporeal life support","volume":"64","author":"Strunina","year":"2019","journal-title":"Biomed Tech (Berl)"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0102","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s00134-015-4015-7","article-title":"Low-dose heparin during extracorporeal membrane oxygenation treatment in adults","volume":"41","author":"Yeo","year":"2015","journal-title":"Intens Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0103","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1053\/j.jvca.2016.10.015","article-title":"Blood and anticoagulation management in extracorporeal membrane oxygenation for surgical and nonsurgical patients: a single-center retrospective review","volume":"31","author":"Buscher","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0104","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/icvts\/ivx251","article-title":"Bivalirudin anticoagulation for left ventricular assist device implantation on an extracorporeal life support system in patients with heparin-induced thrombocytopenia antibodies","volume":"25","author":"Ljajikj","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jocs.14458","article-title":"Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation","volume":"35","author":"Kaseer","year":"2020","journal-title":"J Card Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0106","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1186\/cc10556","article-title":"Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation","volume":"15","author":"Ranucci","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0107","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40256-020-00450-w","article-title":"A review of bivalirudin for pediatric and adult mechanical circulatory support","volume":"21","author":"Taylor","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0108","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12959-022-00401-2","article-title":"Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"20","author":"M'Pembele","year":"2022","journal-title":"Thrombosis J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106089","article-title":"Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: a systematic review and meta-analysis","volume":"177","author":"Liu","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MAT.0000000000001723","article-title":"Bivalirudin versus unfractionated heparin in patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation","volume":"69","author":"Uricchio","year":"2023","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0111","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/CCM.0000000000005033","article-title":"Aganga DO. Comparison of bivalirudin versus heparin for maintenance systemic anticoagulation during adult and pediatric extracorporeal membrane oxygenation","volume":"49","author":"Seelhammer","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MAT.0000000000000691","article-title":"Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation","volume":"64","author":"Berei","year":"2018","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0113","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jtcvs.2006.04.034","article-title":"Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial","volume":"132","author":"Koster","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0114","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10047-015-0846-9","article-title":"Implantation of left ventricular assist devices under extracorporeal life support in patients with heparin-induced thrombocytopenia","volume":"18","author":"Hillebrand","year":"2015","journal-title":"J Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1191\/0267659104pf759oa","article-title":"Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits","volume":"19","author":"Young","year":"2004","journal-title":"Perfusion"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40560-017-0235-y","article-title":"Argatroban for an alternative anticoagulant in HIT during ECMO","volume":"5","author":"Roug\u00e9","year":"2017","journal-title":"J Intens Care"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0117","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0885066621993739","article-title":"Argatroban anticoagulation for adult extracorporeal membrane oxygenation: a systematic review","volume":"37","author":"Geli","year":"2022","journal-title":"J Intens Care Med"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0118","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO Adult and Pediatric Anticoagulation Guidelines","volume":"68","author":"McMichael","year":"2022","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0119","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/vox.12514","article-title":"Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques","volume":"112","author":"Esper","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0120","first-page":"858","article-title":"Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both?","volume":"82","author":"Ranucci","year":"2016","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0121","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-0036-1593414","article-title":"Managing the precarious hemostatic balance during extracorporeal life support: implications for coagulation laboratories","volume":"43","author":"Winkler","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0122","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcrc.2017.02.014","article-title":"Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"39","author":"Sy","year":"2017","journal-title":"J Crit Care"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0123","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jccase.2023.09.003","article-title":"A case of ECPELLA-supported treatment for post-infarction cardiac rupture","volume":"29","author":"Asano","year":"2024","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0124","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.recesp.2019.11.018","article-title":"Massive thrombosis in ECPELLA strategy","volume":"73","author":"Uribarri","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13613-019-0496-9","article-title":"Concurrent initiation of intra-aortic balloon pumping with extracorporeal membrane oxygenation reduced in-hospital mortality in postcardiotomy cardiogenic shock","volume":"9","author":"Chen","year":"2019","journal-title":"Ann Intens Care"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0126","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006930","article-title":"Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation","volume":"11","author":"Vallabhajosyula","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0127","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.1790","article-title":"IABP and VA-ECMO is associated with better outcome than VA-ECMO alone in the treatment of cardiogenic shock in STEMI","volume":"41","author":"van den Brink","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0128","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.120.048792","article-title":"Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study","volume":"142","author":"Schrage","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0129","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032607","article-title":"Impella versus intra-aortic balloon pump in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: an observational study","volume":"13","author":"Yeo","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2022.01.032","article-title":"Mechanical left ventricular unloading in patients undergoing venoarterial extracorporeal membrane oxygenation","volume":"79","author":"Grandin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1051\/ject\/201244015","article-title":"Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution","volume":"44","author":"Ojito","year":"2012","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0132","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cardfail.2024.07.013_bib0133","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/aqy112.350","article-title":"Emergency hemorrhage panel implementation decreases Rotational Thromboelastometry (ROTEM) use for transfusion decisional support","volume":"150","author":"Tokuda","year":"2018","journal-title":"Am J Clin Pathol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642400277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642400277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:40:58Z","timestamp":1728384058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191642400277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":133,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S107191642400277X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.013","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation Medications, Monitoring, and Outcomes in Patients with Cardiogenic Shock Requiring Temporary Mechanical Circulatory Support","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}